ABL Bio and I-Mab Biopharma ink bispecific antibody deal

By Maggie Lynch

- Last updated on GMT

(Image: Getty/designer491)
(Image: Getty/designer491)

Related tags: Monoclonal antibodies, Immunotherapy, Immuno-oncology

ABL Bio and I-Mab Biopharma have partnered to develop bispecific antibodies for immunotherapy.

Bi-specific antibodies (BsAbs) are therapeutic molecules that have shown promise in immunotherapy​, as an alternative to conventional mAbs (monoclonal antibodies). “The benefit of bi-specific antibodies is to link the immune effector cell into the tumor or stimulate two pathways with a synergistic effort,”​ I-Mab’s Raven Lin told us.

In this collaboration, ABL’s BsAb platform will be used to further develop therapeutics. ABL will pay $2.5m (€2.2m) upfront, with the possibility of aggregate payments up to $100m for R&D, regulatory and sales-based milestone payments.

ABL will also pay tiered royalties on net sales, and the firms will share global rights to the molecules.

“This agreement covers four different BsAbs of undisclosed targets, including one global out-licensing, excluding Greater China, to ABL for all indications with a primary focus on oncology, and three other co-development programs,” ​said Lin. 

“We are at fast pace of development towards an integrated pharmaceutical company, we expect to establish more partnerships in near future to support our rapid growth and set up global footprint,” ​Lin added.

I-Mab has also completed in-licensing deals with pharmaceutical companies such as MorphoSys AG​ and Genexine​. In addition, ABL recently entered into a licensing agreement with TRIGR Therapeutics​ to work on BsAbs for oncology.

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Related suppliers

Follow us

Products

View more

Webinars